Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences, Inc. (Nasdaq: PLSE) generates frequent news as it advances its proprietary nPulse nanosecond pulsed field ablation (nsPFA) technology across cardiac and soft tissue applications. The company’s updates focus on clinical trial progress, regulatory milestones, scientific data presentations and early commercial activity for its nsPFA-based systems.
Investors and clinicians following PLSE news will see announcements on key atrial fibrillation programs, including the nPulse Cardiac Surgical System and the nPulse Cardiac Catheter Ablation System. Company releases describe IDE approvals from the U.S. Food and Drug Administration, enrollment of patients in the NANOCLAMP AF and NANOPULSE-AF studies, and feasibility results from European centers using surgical and catheter-based nsPFA devices. Late-breaking data presentations at major cardiology and cardiothoracic surgery meetings are also highlighted.
News flow also covers soft tissue ablation initiatives, such as the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules and research collaborations with academic centers on benign and malignant thyroid tumors. Pulse Biosciences reports publication of first-in-human thyroid data, IDE approvals for thyroid studies, and progress in multi-center trials like PRECISE-BTN.
In addition, PLSE news includes quarterly business updates and financial results, inducement equity grants under Nasdaq rules, and participation in healthcare investor conferences. These items provide context on the company’s operating plans, clinical strategy and capital markets activity. For readers tracking the development of nsPFA technology in atrial fibrillation and thyroid or other soft tissue indications, the Pulse Biosciences news page offers a consolidated view of company disclosures, clinical milestones and corporate events over time.
Pulse Biosciences (Nasdaq: PLSE) announces the appointment of Mitchell E. Levinson as the new Chief Strategy Officer, alongside his existing position on the board. Levinson, a veteran in the medical device industry with over 30 years of experience, aims to drive the company's expansion into multiple specialties, leveraging the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology. This strategic move is expected to enhance the company's dermatology business and facilitate broader applications of NPS technology, addressing unmet healthcare needs.
Pulse Biosciences (PLSE) reported its Q2 2021 financial results, highlighting significant developments in its CellFX System's launch and clinical trials. By the end of Q2, 49 clinics participated in the Controlled Launch Program, with 34 onboarded in that quarter. The company achieved Health Canada approval and initiated Canadian operations. Financially, cash reserves decreased to $47.4 million, with a net loss of $15.3 million. Non-GAAP operating expenses rose to $12.1 million, driven by increased commercialization efforts.
Pulse Biosciences (Nasdaq: PLSE) will release its financial results for Q2 2021 after market close on August 9, 2021. A conference call led by management will follow at 1:30 PM PT. The company focuses on Nano-Pulse Stimulation™ (NPS™) technology, with its CellFX® System being the first commercial product designed for dermatologic applications, allowing for the non-thermal treatment of cells while preserving surrounding tissue. This multi-application platform adopts a utilization-based revenue model, intending to elevate patient outcomes.
Pulse Biosciences (Nasdaq: PLSE) has entered a stock purchase agreement with Robert W. Duggan for 3,048,780 shares at $16.40 each. This deal will clear $41.6 million in debt owed to Duggan, who will invest an additional $8.4 million. Following this transaction, Duggan's ownership will rise to 51% of the company, making it a controlled entity. The funds will support the CellFX System Controlled Launch Program and expand clinical applications for Nano-Pulse Stimulation technology. The closing is expected by July 7, 2021.
Pulse Biosciences, Inc. (Nasdaq: PLSE) announces the first Canadian patient has been treated with the CellFX System, utilizing Nano-Pulse Stimulation (NPS) technology. This significant milestone expands their Controlled Launch program in North America and Europe, enhancing clinical applications for aesthetic dermatology. Dr. Sheetal Sapra, a leading dermatologist, highlights the potential benefits of this novel procedure for patients with common skin lesions. The CellFX System is expected to improve patient outcomes and drive growth, backed by a strategic rollout across major Canadian metropolitan areas.
Pulse Biosciences (Nasdaq: PLSE) has received Health Canada approval for its CellFX® System, enabling its use in dermatological procedures targeting benign lesions, such as sebaceous hyperplasia and warts. This regulatory approval marks a significant milestone, following previous clearances from the FDA and CE mark earlier this year. The company plans to expand its controlled launch of CellFX across select Canadian medical practices and aims to recruit approximately 80 participating practices in North America and Europe. The CellFX System utilizes Nano-Pulse Stimulation™ technology to non-thermally clear targeted cells.
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced its participation in the Jefferies Virtual Healthcare Conference, scheduled for June 2, 2021, at 12:30pm PT. The company is known for its innovative CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, designed to treat various dermatologic conditions effectively. The CellFX System represents a significant advancement in bioelectric medicine, offering a non-thermal method that targets specific cells while preserving surrounding tissues. Interested viewers can access the webcast through the company’s website.
Pulse Biosciences (Nasdaq: PLSE) announced the presentation of four clinical studies on its Nano-Pulse Stimulation (NPS) technology at the ASLMS Virtual Annual Meeting on May 15-16, 2021. The studies focus on treating benign skin lesions, including back acne, common nevi, sebaceous hyperplasia, and cutaneous warts. The NPS technology demonstrated promising efficacy, with significant lesion clearance rates and minimal skin effects. Results suggest NPS could meet unmet medical needs in dermatology. The company's commitment to innovation in bioelectric medicine is highlighted by these advancements.
Pulse Biosciences (PLSE) reported its Q1 2021 financial results, highlighting significant progress in the rollout of its CellFX System Controlled Launch program, onboarding 15 aesthetic practices. The company submitted a final response to Health Canada for the CellFX System Medical Device License, with completion expected by Q2. FDA IDE approval was received for a feasibility study on basal cell carcinoma treatment. Financially, cash and investments reached $59.9 million, though GAAP net loss increased to $18.6 million from $11.9 million YoY, reflecting rising operational expenses.
Pulse Biosciences, Inc. (Nasdaq: PLSE) is set to report its first-quarter 2021 financial results on May 10, 2021, post-market close. A conference call will follow at 1:30 PM PT, where management will discuss the financial outcomes. Interested investors can join by dialing the provided numbers or by accessing the webcast available on the company's investor relations website. Pulse Biosciences is dedicated to advancing its Nano-Pulse Stimulation™ (NPS™) technology, notably through its CellFX® System, which targets dermatologic conditions while ensuring non-thermal clearance of cells.